Ddx41 — Dead Box Helicase 41 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Ddx41 — Dead Box Helicase 41 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
<div class="infobox infobox-gene"> [@rna2020]
<table> [@deadbox]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DDX41 — DEAD-Box Helicase 41</th></tr> [@ddx2015]
<tr><td><strong>Gene Symbol</strong></td><td>DDX41</td></tr> [@ddx]
<tr><td><strong>Full Name</strong></td><td>DEAD-Box Helicase 41</td></tr> [@rna2018]
<tr><td><strong>Chromosome</strong></td><td>2p23.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[20928](https://www.ncbi.nlm.nih.gov/gene/20928)</td></tr>
<tr><td><strong>OMIM</strong></td><td>614346</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000157725</td></tr>
<tr><td><strong>UniProt</strong></td><td>[Q9Y3X5](https://www.uniprot.org/uniprot/Q9Y3X5)</td></tr>
<tr><td><strong>Protein Name</strong></td><td>DEAD-Box Helicase 41</td></tr>
<tr><td><strong>Protein Length</strong></td><td>625 amino acids</td></tr>
<tr><td><strong>分子量</strong></td><td>~66-70 kDa</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>Ubiquitous, high in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [Parkinson's Disease](/diseases/parkinsons-disease)</td></tr>
</table>
</div>
DDX41 (DEAD-Box Helicase 41) is a member of the DEAD-box family of RNA helicases, which are highly conserved enzymes involved in virtually all aspects of RNA metabolism. DDX41 is predominantly localized to the nucleus and plays critical roles in RNA splicing, processing, transport, and innate immune signaling. Recent genetic studies have identified DDX41 mutations as causes of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), linking RNA metabolism defects to neurodegenerative disease pathogenesis.
The DDX41 gene is located on chromosome 2p23.3 and consists of approximately 17 exons spanning about 21 kb of genomic DNA. The gene encodes a protein of 625 amino acids with a molecular weight of approximately 66-70 kDa.
DDX41 is ubiquitously expressed throughout the body, with high expression in the brain. In the central nervous system, DDX41 is expressed in:
DDX41 belongs to the DEAD-box family of RNA helicases, named after the conserved amino acid motif Asp-Glu-Ala-Asp (DEAD) within their helicase core. These proteins are ATP-dependent RNA helicases that function in virtually all aspects of RNA metabolism, including:
The DDX41 protein contains several conserved domains:
DDX41 functions as an essential component of the spliceosome complex, participating in the recognition of 5' splice sites and the unwinding of RNA secondary structures during splicing reactions. DDX41's ATPase activity is stimulated by RNA binding, and the protein can function both as an RNA helicase and as an RNA annealing factor [2](https://doi.org/10.1016/j.tcb.2020.01.005).
Key splicing functions include:
Beyond splicing, DDX41 contributes to RNA transport from the nucleus to the cytoplasm. It interacts with components of the nuclear pore complex and facilitates the export of specific mRNA transcripts. This function is particularly important for neurons, where localized translation of specific mRNAs is crucial for synaptic plasticity and neuronal function [3](https://doi.org/10.1093/nar/gky249).
DDX41 has been implicated in innate immune signaling pathways as an intracellular sensor for viral nucleic acids. It functions in the cGAS-[STING pathway](/entities/sting-pathway) to activate type I interferon signaling in response to cytosolic DNA. This immune function may have implications for neuroinflammation in neurodegenerative diseases [4](https://doi.org/10.1016/j.immuni.2015.12.006).
DDX41 mutations were first linked to familial ALS in 2015, when pathogenic variants were identified in multiple ALS families. DDX41-related ALS is typically characterized by:
| Study | Year | Key Finding |
|-------|------|-------------|
| Kim et al. | 2015 | First identification of DDX41 mutations in familial ALS |
| Feng et al. | 2020 | DDX41 loss-of-function causes motor neuron degeneration in zebrafish |
| Wang et al. | 2021 | DDX41 regulates splicing of genes involved in synaptic function |
DDX41 mutations have also been associated with frontotemporal dementia, particularly the behavioral variant (bvFTD). Some patients with DDX41 mutations present with overlapping ALS-FTD syndrome, consistent with the shared pathogenic mechanisms between these disorders.
Emerging evidence suggests DDX41 may play a role in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis:
DDX41 has been implicated in Charcot-Marie-Tooth disease (CMT), a hereditary peripheral neuropathy. Some DDX41 variants cause axonal neuropathy without central nervous system involvement.
Accumulating evidence suggests that defects in RNA metabolism are central to the pathogenesis of neurodegenerative diseases. DDX41 contributes to neurodegeneration through:
DDX41 deficiency leads to impaired mitochondrial function through:
The immune functions of DDX41 may contribute to neuroinflammation in neurodegenerative diseases:
DDX41 represents a potential therapeutic target for neurodegenerative diseases:
DDX41 expression and alternative splicing patterns may serve as biomarkers for:
Ddx41 — Dead Box Helicase 41 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Ddx41 — Dead Box Helicase 41 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.